CD4 T cell
measurements in the management of antiretroviral therapy--A review with an emphasis on pediatric HIV-infected patients.
CD4 T cell
help is limiting and selective during the primary B cell response to influenza virus infection.
Incomplete CD4 T cell
recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell
activation and turnover.
Characteristics, determinants, and clinical relevance of CD4 T cell
recovery to <500 cellsl/[micro]L in HIV type 1-infected individuals receiving potent antiretroviral therapy.
In some cases, treatment is interrupted according to a scheduled time frame, while other studies have used CD4 T cell
counts or viral load as indicators of when to stop or re-initiate therapy.
We also assessed the reproducibility of the Capcellia assay by comparison of CD4 T cell
counts determined by two trained technicians (Fig.
CD4 T cell
enumeration is the single most important clinical parameter used by physicians to monitor disease progression and to determine proper therapy for patients infected with HIV.
The identification of the major HIV CD4 T cell
reservoir will be instrumental in developing therapeutic strategies to selectively target HIV infected Tfh cells," says Prof.
The CD4 T cell
count in peripheral blood is an important prognostic marker in the context of HIV infection.
Though viral load control in HIV-infected patients is an attainable goal with the current potent HAART regimen, the magnitude of CD4 restoration among patients remains variable and the length of time patients spend with low CD4 T cell
counts is clearly associated with a higher morbidity," said Yves Levy MD, PhD, Scientific Director of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) Vaccine Program, Service d'Immunologie Clinique, Hypital Henri Mondor, Creteil, France and Inserm, Principle Investigator and lead author of the publication.
One of the first indications of this premise was the observation that viral loads increase and CD4 T cell
counts fall in patients stopping therapy.
Recent reports from Steven Deeks, MD, stating that CD4 T cell
response is sustained even after the failure of PI-based regimens lend a further dimension to the issue, posing the question of whether there is some inherent benefit of PIs or PI-based regimens that makes them useful even beyond their obvious mechanism of suppressing HIV.